14 results about "Gene panel" patented technology

Described herein are gene panel compositions and methods of use thereof for spatial omic analysis in biological samples. The gene panels may be organized into distinct modules that target various aspects of immune response, tumor biology, and intercellular communication within the microenvironment. These methods involve spatial omic techniques, such as spatial transcriptomics, to localize gene expression across tissue sections, providing detailed insights into immune cell infiltration, immune checkpoint activation, and tumor-immune interactions. The disclosed compositions and methods are applicable for diagnostics, monitoring therapeutic responses, and guiding personalized treatment strategies. The modular design of the gene panels allows for customization based on specific research or clinical objectives.

This disclosure provides a method for treating a cancer patient comprising administering to the patient a therapeutically effective amount of an anti-PD-1 antagonist, for example, an anti-PD-1 or anti-PD-L1 antibody, in combination with an indolamine 2,3-dioxygenase inhibitor, wherein the patient is identified as exhibiting a combined biomarker comprising (a) a high IFNγ inflammatory signature score and (b) a low tryptophan 2,3-dioxygenase 2 (TDO2) gene expression score. The high IFNγ inflammatory signature score is determined by measuring the expression of a panel of IFNγ-related inflammatory genes in a cancer sample obtained from the patient, wherein the gene panel comprises, for example, IFNγ, CXCL10, CXCL9, HLA-DRA, IDO1, and STAT1. In some respects, the gene panel also includes CCR5, CXCL11, GZMA, and PRF1.In some aspects, the genetic panel comprises CXCR6, TIGIT, PD-L1, PD-L2, LAG3, NKG7, PSMB10, CMKLR1, CD8A, IDO1, CCL5, CXCL9, HLA.DQA1, CD276, HLA.DRB1, STAT1, HLA.E and TDO2.

The disclosure provides a method for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antagonist, e.g., an anti-PD-1 or anti-PD-L1 antibody, in combination with an indoleamine 2,3-dioxygenase inhibitor, wherein the subject is identified as exhibiting a combined biomarker comprising (a) a high IFNγ inflammatory signature score and (b) a low tryptophan 2,3-dioxygenase 2 (TDO2) gene expression score. The high IFNγ inflammatory signature score is determined by measuring the expression of a panel of IFNγ related inflammatory genes in a cancer sample obtained from the subject, wherein the gene panel comprises, e.g., IFNγ, CXCL10, CXCL9, HLA-DRA, IDO1, and STAT1. In some aspects, the gene panel further comprises CCR5, CXCL11, GZMA, and PRF1. In some aspects, the gene panel comprises CXCR6, TIGIT, PD-L1, PD-L2, LAG3, NKG7, PSMB10, CMKLR1, CD8A, IDO1, CCL5, CXCL9, HLA.DQA1, CD276, HLA.DRB1, STAT1, HLA.E, and TDO2.

Provided herein are methods of treating a patient afflicted with a tumor according to the tumor's microenvironments (TME). Also provided are gene panels that can be used for identifying a human subject afflicted with a cancer suitable for treatment with a particular therapeutic agent based on the subject's TME.

Disclosed is a gene panel which can evaluate lung adenocarcinoma molecular subtype and survival risk, and an application of a reagent, which detects the gene expression level of the gene panel, in preparing a product. The product is used for determining lung adenocarcinoma molecular subtype and evaluating lung adenocarcinoma patient survival risk. The product comprises a Next-Generation Sequencing (NGS) detection reagent kit, a fluorescence quantitative PCR detection reagent kit, a gene chip and a protein microarray. Also disclosed is a method which uses the detection reagent kits to evaluate lung adenocarcinoma molecular subtype and survival risk.

The application relates to the field of biotechnology, in particular to a probe composition for detecting a salivary gland tumor gene panel and application thereof, and further relates to a library construction method, a sequencing method, a kit and a device for the salivary gland tumor gene panel. The probe composition can capture nucleic acid molecules of multiple genes related to salivary gland tumors, such as AKT1, APC, AR, ARID1A, ATM, AXIN1, BAP1, BARD1, BCOR, BRAF, BRCA1, BRCA2, CDH1, CDK11B, CDKN2A, CDKN2B, CREBBP, CTNNB1, CYLD, EGFR and EP300. The nucleic acid molecules in a sample to be analyzed are captured by using the probe composition, and library construction and sequencing are carried out; and the analysis result of the sequencing data is helpful to improving the diagnosis accuracy of salivary gland tumors.

The application discloses a gene panel for detecting retinal pigment degeneration and application thereof, the gene panel comprising PRPF31, TFPT, NDUFA3, OSCAR, USH2A, EYS, RPGR, RHO, RP1, ABCA4, RDH12, CRB1, CNGA1, SNRNP200, CERKL, PDE6B, PROM1, CEP290, RP2, CYP4V2, RPE65, PRPF6 and CNGB1. The gene panel comprises PRPF31 and its upstream and downstream genes, and covers high-frequency mutation genes in an RP population. Through high-density probe design on target regions of the genes, not only the detection cost is reduced, but also precise diagnosis of clinical typing of RP and comprehensive genetic evaluation of PRPF31-RP patients can be realized.

The present application relates to the technical field of gene detection, in particular to a gene panel, method, device and use for somatic cell variation detection of SLC35A2 gene. The present application provides a gene panel, which can target capture the entire SLC35A2 gene related region, including exons, introns, promoters and enhancers, and carry out somatic cell variation detection, including SNVs, small Indels and SVs. The panel is used for detection of refractory epilepsy surgical brain tissue specimens, and can genetically diagnose mild cortical dysplasia with oligodendrogliosis epilepsy (MOGHE). This kind of disease is a new subtype of focal cortical dysplasia newly included by the International League Against Epilepsy in 2022. The panel has high variation detection rate and more comprehensive variation detection types.

The present invention relates to a gene panel for predicting the responsiveness of renal cancer patients to radiotherapy. In the present invention, the responsiveness of patients to stereotactic body radiotherapy can be predicted with high accuracy by only biopsy of a small amount of tissue, thereby maximizing the efficiency of radiotherapy for patients with difficulty in surgery and at the same time, providing the advantage of preserving renal function.

The disclosure provides a method for treating a subject afflicted with a tumor comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof, wherein the subject is identified as having a low stromal gene signature score. In some aspects, the low stromal gene signature score is determined by measuring the expression of a panel of stromal genes in a tumor sample obtained from the subject, wherein the stromal gene panel comprises at least four genes selected from CDH1, CDH2, MMP1, MMP2, ITGA1, ITGA2, ITGA3, ITGA5, ITGA7, ITGA11, TGFB1, and TGFB1; at least four genes selected from TGFB1, TGFBR2, ACTA2, COL4A1, TAGLN, SH3PXD2A, TWIST1, ZEB1, and ZEB2; or MMP2 and MMP9.

The disclosure provides methods and compositions, e.g., kits and microarray, for assessing the immune response in a murine tumor model based on the expression of a gene panel that characterizes tumor immune interactions.

This slide specimen confirmation assistance system comprises: an image acquisition means for acquiring, for a gene panel test, an image of a first stained slide specimen in which a first target region is marked by a physician; a first output means for outputting the result of estimation of the tumor cell content proportion of the first target region; an identification means for identifying a second target region on the first stained slide specimen; a second output means for outputting the result of estimation of the tumor cell content proportion of the second target region; and a first generation means for generating, according to an instruction from a user, target region change information indicating that the second target region is to be used.

The embodiment of the invention provides a gene panel, a probe, a kit and a method for detecting bony mandibular prolapse, and belongs to the technical field of gene detection. The gene panel for detecting the bony mandibular prolapse comprises a plurality of target genes. According to the scheme, the reported bony mandibular preprocess related genes and the potential core pathogenic genes screened through the network propagation algorithm are integrated at the same time, a genetic detection panel which is wider in coverage and higher in relevance is constructed, and systematic capture and high-confidence identification of the bony mandibular preprocess pathogenic genes are achieved. The panel can detect functional mutation of multiple gene loci at a time, the problem that key genetic factors are omitted in traditional single-gene detection is solved, and the detection sensitivity and specificity are improved.

The application provides an immunohistochemical combined gene detection system for early screening of skin lymphoma, which integrates ten function modules of intelligent sample pretreatment, multi-target synchronous immunohistochemical staining, high-resolution digital pathology scanning, laser microdissection assisted micro-nucleic acid extraction, skin lymphoma specific gene panel amplification, high-throughput sequencing, multi-modal data fusion, intelligent risk assessment, dynamic follow-up early warning and standardized report generation. The system realizes accurate matching of spatial localization of immunophenotype and high-sensitivity gene variation detection on the same tissue section, and automatically outputs individualized risk score and diagnosis suggestion by fusing multi-dimensional data through artificial intelligence algorithm. Compared with the traditional method, the detection rate and interpretation consistency of early skin lymphoma are significantly improved, the whole process is automatically and standardized, and the system is suitable for clinical early screening, differential diagnosis and dynamic monitoring, and has important application prospect.